COVID 19

COVID‑19 (SARS‑CoV‑2)* rapid antigen testing

BD Veritor™ Plus System

Used as part of a comprehensive coronavirus mitigation program, fast, easy-to-use testing for SARS-CoV-2 (the novel or new coronavirus that causes COVID-19) provides health care workers information they can use to actively detect the virus and decrease the likelihood of spread.

What is COVID‑19?

There are seven known human coronaviruses¹. SARS-CoV-2, more commonly referred to as COVID-19, is a novel or new virus which means a person's immune system has not been exposed to it yet. SARS-CoV-2 is the coronavirus that caused the COVID-19 pandemic².

 

In COVID-19, the name reflects the following:²

COVID-19 explained

To learn more about how to slow the spread of COVID-19, visit the CDC website for more information.

Why rapid point-of-care testing matters

As the global healthcare community searches for effective methods for addressing COVID-19, the important role of testing is becoming more apparent. There are currently two kinds of testing available for SARS-CoV-2: diagnostic testing that detects either genetic material (RNA) or proteins (antigens) from the infecting virus, and antibody testing that detects the body’s immune response to infection (antibodies).

 

The BD Veritor™ Plus System provides simple and reliable rapid antigen testing at the point-of-care.

Types of respiratory diagnostic testing

diagnostic testing
Rapid antigen test icon

Rapid antigen test

Detects proteins (antigens) from the infecting virus

Molecular icon

Molecular diagnostic (PCR) test

Detects genetic material (RNA) from the infecting virus

antibody testing
Serology icon

Serology test

Detects the body’s immune response to infection (antibodies)

BD Veritor™ System for Rapid Detection of SARS‑CoV‑2*

The BD Veritor™ System for Rapid Detection of SARS‑CoV‑2* antigen test detects nucleoproteins from the SARS‑CoV‑2 virus in as little as 15 minutes⁴, and can be conducted at the point-of-care.

The BD Veritor™ Plus System provides rapid, reliable results, and offers one-button functionality for workflow flexibility, allowing health care professionals to confidently use the Analyzer.

Nasal sample icon

Simple sample collection

Clock icon

Rapid, reliable results

BD Veritor Plus Analyzer icon

Convenient portability

Computer screen icon

Reporting options available

                                            

Read more about our simplified testing and result reliability.

How to perform COVID‑19 testing with the BD Veritor™ Plus System*

The BD Veritor™ System for Rapid Detection of SARS‑CoV‑2* antigen test detects proteins from the SARS‑CoV‑2 virus. A nasal swab is used to collect the specimen from a patient suspected of having COVID‑19. The sample is prepared, added to the assay cartridge, incubated and then interpreted by the Analyzer.

For complete instructions for use, refer to our user documentation.

Collect patient sample

Collect patient sample

Remove cap and insert swab into tube

Remove cap and insert swab into tube

Mix sample with reagent, then remove swab

Take care not to splash contents out of the tube

Mix sample with reagent, then remove swab

Close dispensing cap, then dispense sample into test device

Close dispensing cap, then dispense sample into test device

The Analyzer interprets the results
For Walk Away mode, insert test device immediately
For Analyze Now mode, insert test device after 15-minute test incubation period

The Analyzer interprets the results

To learn more about how to administer rapid antigen testing with the BD Veritor™ Plus System, see our simple user guides in the resource library.

BD Veritor™ Plus System ordering and reimbursement

As your facility continues to provide valuable rapid diagnostic testing, you may need to reorder. Please click here for more information.

REFERENCES

  1. https://www.yalemedicine.org/conditions/coronavirus
  2. https://www.cdc.gov/coronavirus/2019-ncov/cdcresponse/about-COVID-19.html
  3. BD Veritor System for Rapid Detection of SARS-CoV-2 [package insert]. 256082. Franklin Lakes, NJ: Becton, Dickinson and Company.